```html

Severe Asthma – A Complete Patient Guide

Overview

Severe asthma is a subset of asthma in which symptoms and airflow limitation persist despite high‑dose inhaled corticosteroids (ICS) combined with other controllers, or when these medications cannot be tolerated. It accounts for roughly 5–10 % of all asthma cases yet contributes disproportionately to asthma‑related morbidity, health‑care utilization, and mortality.

• Who it affects: Adults and children of any age, but the highest burden is seen in adolescents and middle‑aged adults.
• Prevalence: According to the Global Asthma Report 2022, ~339 million people worldwide have asthma; about 17–34 million have severe asthma <sup>1</sup>. In the United States, the CDC estimates that 1.5 % of the population (≈5 million) lives with severe asthma <sup>2</sup>.

Symptoms

Severe asthma presents with the classic features of asthma, but they are more intense, frequent, and less responsive to standard therapy.

Typical symptoms

• Wheezing: High‑pitched, musical sound on exhalation that may be heard at rest.
• Chest tightness: A feeling of pressure or “band” around the chest.
• Shortness of breath: Difficulty catching breath, especially during activity or at night.
• Persistent cough: Often dry, worsening at night or early morning.
• Frequent night‑time awakenings: ≥2 times per week due to asthma symptoms.
• Exercise‑induced bronchoconstriction: Symptoms triggered by physical activity.

Red‑flag symptoms that suggest poor control or an imminent exacerbation

• Increasing use of reliever inhaler (≥2 puffs every day).
• Decreased peak expiratory flow (PEF) by >20 % from personal best.
• Speech becoming difficult, unable to finish a sentence.
• Loud wheezing or noisy breathing at rest.
• Blue lips or fingertips (cyanosis).

Causes and Risk Factors

Severe asthma is a heterogeneous disease. The underlying mechanisms can be broadly divided into “type‑2 (eosinophilic) inflammation” and “non‑type‑2 (neutrophilic or paucigranulocytic) inflammation”.

Primary causes

• Genetic predisposition: Polymorphisms in IL4R, ORMDL3, and ADAM33 genes increase susceptibility.
• Allergic sensitization: House dust mites, pet dander, pollen, mold.
• Environmental exposures: Tobacco smoke, air pollution, occupational irritants (e.g., silica, isocyanates).
• Respiratory infections: Early‑life viral infections (RSV, rhinovirus) can set a trajectory toward severe disease.
• Comorbid conditions: Chronic rhinosinusitis with nasal polyps, gastroesophageal reflux disease (GERD), obesity, obstructive sleep apnea.

Risk factors for developing severe asthma

• History of frequent (< 2 ×/year) or severe exacerbations.
• Persistent airflow limitation (FEV₁ < 60 % predicted).
• High blood or sputum eosinophil count (> 300 cells/µL) indicating type‑2 inflammation.
• Smoking (active or significant second‑hand exposure).
• Low socioeconomic status—often linked to poor access to care and higher exposure to triggers.

Diagnosis

Diagnosing severe asthma requires confirming that asthma is present, assessing its severity, and ruling out mimicking conditions such as chronic obstructive pulmonary disease (COPD) or vocal‑cord dysfunction.

Step‑wise evaluation

1. Detailed medical history & physical exam: Frequency of symptoms, trigger exposure, medication use, and comorbidities.
2. Spirometry with bronchodilator reversibility: FEV₁/FVC < 0.70 plus ≥12 % and 200 mL increase after bronchodilator confirms asthma.
3. Peak expiratory flow (PEF) diary: Records variability over 2–4 weeks; > 20 % diurnal variation supports diagnosis.
4. Fractional exhaled nitric oxide (FeNO): Elevated FeNO (> 25 ppb) points to eosinophilic inflammation.
5. Blood eosinophil count & sputum analysis: Helps phenotype disease and guides biologic therapy.
6. Chest radiography or CT (when indicated): Excludes alternative diagnoses (e.g., bronchiectasis).
7. Allergy testing (skin prick or serum IgE): Identifies allergic sensitizations for targeted management.

Criteria for “severe asthma” (GINA 2023)

Patients meet one of the following despite maximal optimized therapy:

• Requires high‑dose ICS + long‑acting β₂‑agonist (LABA) + another controller (e.g., leukotriene receptor antagonist) to prevent uncontrolled symptoms.
• Remains uncontrolled despite such therapy (≥ 2 ≥ daytime symptoms/week, night‑time symptoms ≥ 1 ×/month, or ≥ 1 exacerbation requiring oral steroids in the past year).

Treatment Options

Management hinges on a stepwise approach, combining pharmacologic therapy, biologic agents, and non‑pharmacologic measures.

1. Controller Medications

• High‑dose inhaled corticosteroids (ICS): Fluticasone propionate 500–1000 µg BID, Budesonide 800–1600 µg BID.
• Long‑acting β₂‑agonists (LABA): Formoterol or Salmeterol combined with ICS in a single inhaler.
• Long‑acting muscarinic antagonists (LAMA): Tiotropium Respimat 5 µg daily—beneficial as add‑on.
• Leukotriene receptor antagonists (LTRAs): Montelukast 10 mg nightly; useful for aspirin‑exacerbated respiratory disease.

2. Oral/Systemic Corticosteroids

Short bursts (5‑10 days) for acute exacerbations; chronic use is discouraged due to side‑effects (osteoporosis, diabetes, hypertension). Referral to an asthma specialist is advised if > 2 courses/year are needed.

3. Biologic Therapies (Targeted for Phenotype)

Biologic	Target	Indication
Omalizumab	IgE	Allergic severe asthma, IgE 30‑700 IU/mL, ≥ 1 year sensitization
Mepolizumab / Reslizumab / Benralizumab	IL‑5 pathway	Eosinophilic asthma, blood eosinophils ≥ 150‑300 cells/µL
Dupilumab	IL‑4Rα (blocks IL‑4 & IL‑13)	Type‑2 asthma with elevated FeNO or eosinophils; also eczema or chronic sinusitis with polyps

4. Bronchial Thermoplasty (Procedural)

Endoscopic delivery of controlled radiofrequency energy to reduce airway smooth‑muscle mass. Recommended for adults with severe, persistent asthma who remain uncontrolled despite maximal medical therapy. Evidence shows a 30‑40 % reduction in severe exacerbations over five years <sup>3</sup>.

5. Lifestyle & Environmental Control

• Smoking cessation (including vaping).
• Allergen avoidance: dust‑mite‑proof covers, HEPA air cleaners, pet removal if sensitized.
• Regular physical activity—tailored to tolerance.
• Vaccinations: influenza annually, COVID‑19 booster, pneumococcal (PCV20/PPV23) per CDC guidelines.

6. Action Plan & Self‑Management

All patients should have a written, personalized asthma action plan that specifies daily controller doses, rescue inhaler use, and steps for worsening symptoms.

Living with Severe Asthma

Successful long‑term control combines medical treatment with daily habits that minimize triggers and monitor lung function.

Daily Management Checklist

1. Medication adherence: Use a dose‑counter inhaler or smartphone reminder.
2. Peak flow monitoring: Record twice daily; know your personal best and red‑zone thresholds.
3. Trigger journal: Note exposures (smoke, pollen, stress) that precede symptom spikes.
4. Regular follow‑up: At least every 3–6 months with your asthma specialist; more frequently if unstable.
5. Weight management: Aim for BMI < 30 kg/m²; weight loss improves control in obese patients.
6. Stress reduction: Mindfulness, yoga, or counseling can lower adrenergic triggers.

Psychosocial Support

Severe asthma is associated with anxiety, depression, and reduced quality of life. Refer to mental‑health professionals, patient‑support groups (e.g., American Lung Association’s Asthma Community), and consider pulmonary rehabilitation programs.

Prevention

While a genetic predisposition cannot be altered, many modifiable factors reduce risk of progression to severe disease.

• Early asthma control: Initiate low‑dose ICS at diagnosis; avoid stepping down too quickly.
• Vaccination: Prevent respiratory infections that can worsen airway inflammation.
• Environmental hygiene: Keep indoor humidity < 50 %; eliminate mold; use pollen‑free filters during high‑pollen seasons.
• Avoid tobacco exposure: Both active smoking and second‑hand smoke are linked with poorer response to ICS.
• Occupational protection: Use respirators or engineering controls when exposed to irritants in the workplace.

Complications

If severe asthma is inadequately treated, the following complications may arise:

• Frequent severe exacerbations leading to emergency department visits or ICU admission.
• Fixed airflow obstruction (irreversible decline in FEV₁).
• Chronic oral corticosteroid toxicity: osteoporosis, cataracts, adrenal suppression, hypertension, diabetes.
• Psychological impact: anxiety, depression, reduced school or work productivity.
• Rare but serious: fatal asthma attack (approximately 1 in 150,000 adults with asthma yearly in the U.S.) <sup>4</sup>.

When to Seek Emergency Care

---

References:

1. Global Asthma Report 2022. Global Asthma Network. https://ginasthma.org/2022-report
2. Centers for Disease Control and Prevention (CDC). Asthma Surveillance Data. https://www.cdc.gov/asthma/data.htm
3. Cheng G, et al. Long‑Term Outcomes of Bronchial Thermoplasty for Severe Asthma. J Allergy Clin Immunol. 2021;147(3):789‑796.
4. National Center for Health Statistics. Asthma Mortality Data, 2020. https://www.cdc.gov/nchs/fastats/asthma.htm
5. GINA 2023 Report. Global Strategy for Asthma Management and Prevention. https://ginasthma.org/gina-reports/

```